RAC 2.20% $1.78 race oncology ltd

Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-9

  1. 827 Posts.
    lightbulb Created with Sketch. 127
    Thanks for yet another well written and detailed ann that all shareholders can understand.
    A shame about the timing of release but it doesnt take away from what these results mean for the future.

    very exciting.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.